232 related articles for article (PubMed ID: 34715598)
1. The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality.
Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; Wu K; McIntyre RS; Ning Y
J Psychiatr Res; 2021 Dec; 144():312-319. PubMed ID: 34715598
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation.
Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; McIntyre RS; Ning Y
J Affect Disord; 2022 May; 304():78-84. PubMed ID: 35176337
[TBL] [Abstract][Full Text] [Related]
4. Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation.
Zhou Y; Wang C; Lan X; Li W; Chao Z; Wu K; McIntyre RS; Ning Y
Front Psychiatry; 2022; 13():779326. PubMed ID: 35586411
[TBL] [Abstract][Full Text] [Related]
5. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
McIntyre RS; Rosenblat JD; Rodrigues NB; Lipsitz O; Chen-Li D; Lee JG; Nasri F; Subramaniapillai M; Kratiuk K; Wang A; Gill H; Mansur RB; Ho R; Lin K; Lee Y
Psychiatry Res; 2021 Aug; 302():113993. PubMed ID: 34034067
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Affect Disord; 2019 Mar; 246():241-247. PubMed ID: 30590286
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P
Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of ketamine response in treatment-resistant major depression.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
[TBL] [Abstract][Full Text] [Related]
12. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
Bottemanne H; Morlaas O; Claret A; Sharot T; Fossati P; Schmidt L
JAMA Psychiatry; 2022 Nov; 79(11):1124-1132. PubMed ID: 36169969
[TBL] [Abstract][Full Text] [Related]
14. Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression.
Wu Z; Gan Y; Li N; Lan X; Wang C; Zhang F; Liu H; Li W; Ye Y; Hu Z; Ning Y; Zhou Y
J Affect Disord; 2023 Aug; 334():152-158. PubMed ID: 37156269
[TBL] [Abstract][Full Text] [Related]
15. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH
Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430
[TBL] [Abstract][Full Text] [Related]
16. Anhedonia in bipolar depression treated with ketamine.
Wilkowska A; Wiglusz MS; Arciszewska-Leszczuk A; Gałuszko-Węgielnik M; Cubała WJ
Bipolar Disord; 2024 Jun; 26(4):356-363. PubMed ID: 38311367
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
18. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive Effects of Ketamine and Esketamine for Treatment-Resistant Major Depressive Disorder: A Systematic Review.
Souza-Marques B; Santos-Lima C; Araújo-de-Freitas L; Vieira F; Jesus-Nunes AP; Quarantini LC; Sampaio AS
Harv Rev Psychiatry; 2021 Sep-Oct 01; 29(5):340-350. PubMed ID: 34366408
[TBL] [Abstract][Full Text] [Related]
20. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
